SenesTech Working with TriptoBIO on Biosynthetic Triptolide
SenesTech (NASDAQ: SNES), a leader in rodent fertility control, has announced its collaboration with Danish company TriptoBIO to develop biosynthetic triptolide, an active ingredient in their EPA-registered contraceptive, ContraPest. This partnership aims to enhance the efficiency and cost-effectiveness of ContraPest by ensuring consistent quality and reducing production costs compared to botanically sourced triptolide from China. CEO Joel Fruendt highlighted the potential for improved market expansion and sustainability through this initiative, which aligns with the company's mission to advance pest management practices.
- Collaboration with TriptoBIO focused on developing biosynthetic triptolide.
- Potential for lower production costs and improved consistency in quality for ContraPest.
- Possibility for expanded market reach domestically and internationally.
- None.
PHOENIX, March 14, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today confirmed news reports that the Company has been working with the Danish company TriptoBIO on the development of biosynthetic triptolide, one of the active ingredients in ContraPest.
"We have been working with TriptoBIO for quite some time on biosynthetic triptolide, and have a letter of intent in place for its development and will be working collaboratively to have it approved by the EPA," said Joel Fruendt, SenesTech's CEO. "The recent press in Europe about their advances has highlighted the efficacy and sustainability of ContraPest, as well as some of the benefits of a biosynthetic source of triptolide."
Mr. Fruendt continued, "From our perspective, biosynthetic triptolide brings two very distinct advantages to ContraPest. One, biosynthetic production is typically more consistent in its quality and availability, compared with botanically derived triptolide from China, our current source. Two, biosynthetic production is typically much less expensive than botanical purification, allowing us to lower the price of ContraPest and greatly expand our market domestically and internationally."
"Working together, SenesTech and TriptoBIO have the aligned mission to change the world of pest management for the better," Mr. Fruendt concluded.
About SenesTech
We are the experts in rat fertility control. Our passion is to create a healthy environment by better controlling rat pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest, the only U.S. EPA registered contraceptive for male and female rats. ContraPest fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses, and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we are committed to improving the health of the world by humanely managing animal populations through fertility control.
For more information visit https://senestech.com/ and https://contrapeststore.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our belief that the surge of acceptance of ContraPest will be key to building on our growth trend and even accelerating it in 2023. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the impacts and implications of the COVID-19 pandemic, the successful commercialization of our products, market acceptance of our products, regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, our Registration Statement on Form S-1, filed with the Securities and Exchange Commission on October 24, 2022, as amended on November 15, 2022, and the final prospectus related thereto. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACT:
Investors: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC,
602-889-9700, senestech@lythampartners.com
Press: Nicole Williams, Chief Revenue Officer, SenesTech, Inc., 928-779-4143
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc.,
928-779-4143
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-working-with-triptobio-on-biosynthetic-triptolide-301770806.html
SOURCE SenesTech, Inc.
FAQ
What is SenesTech's recent collaboration about?
How does biosynthetic triptolide benefit ContraPest?
When was the collaboration with TriptoBIO announced?
What is the stock symbol for SenesTech?
